{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041985","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.668399+00:00","generated_at":"2026-05-16T20:06:48.464939+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Strata Skin Sciences Q3 revenue $6.9M (-21% YoY); net loss narrows to $1.6M","bullets":["Revenue $6.9M (-21% YoY); net loss $1.6M (EPS -$0.36) vs $2.1M loss (EPS -$0.51) last year.","Global recurring revenue $5.5M (+3% YoY); equipment revenue $1.4M (-60%).","EBITDA slightly positive vs -$0.2M; cash $7.1M after $2.4M registered direct offering.","CMS recognized expanded CPT codes for XTRAC; COFEPRIS cleared TheraClearX in Mexico.","XTRAC install base 838 (-6); TheraClearX 161; avg gross billings per device $5,981 (+8.5%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041985","json":"https://secwatch.observer/filing/0001140361-25-041985.json","markdown":"https://secwatch.observer/filing/0001140361-25-041985.md","text":"https://secwatch.observer/filing/0001140361-25-041985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036125041985/0001140361-25-041985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036125041985/ef20058935_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:06:48.464939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}